SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
GNCA
--
0.00%
--
AstraZeneca Nirsevimab Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha · 2d ago
Mid-Afternoon Market Update: Nasdaq Turns Higher; Kraton Shares Plummet
Toward the end of trading Thursday, the Dow traded down 0.98% to 26280.13 while the NASDAQ rose 0.37% to 10582.30. The S&P also fell, dropping 0.49% to 3,242.49.
Benzinga · 3d ago
BLNK, PEIX, GTX and BEP among midday movers
Seeking Alpha · 3d ago
Mid-Day Market Update: Crude Oil Down 3%; At Home Group Shares Spike Higher
Midway through trading Thursday, the Dow traded down 1.20% to 26221.54 while the NASDAQ rose 0.01% to 10,543.55. The S&P also fell, dropping 0.76% to 3,233.65.
Benzinga · 3d ago
Healthcare - Top 5 Gainers / Losers
Seeking Alpha · 3d ago
Mid-Morning Market Update: Markets Open Lower; Procter & Gamble Tops Q4 Views
Following the market opening Thursday, the Dow traded down 1.81% to 26060.12 while the NASDAQ fell 0.85% to 10453.02. The S&P also fell, dropping 1.39% to 3,213.22.
Benzinga · 3d ago
Genocea Biosciences Earlier Reported Will Present Prelim. Data For Neoantigen Vaccine GEN-009 In Combo With Checkpoint Inhibitors: '3 of 5 patients achieved separate RECIST responses after GEN-009 administration'
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present initial clinical data today on the first five patients from Part B of the ongoing
Benzinga · 3d ago
Genocea under pressure on underwhelming neoantigen vaccine data
Seeking Alpha · 3d ago
LYG, BBVA among premarket losers
Seeking Alpha · 4d ago
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 4d ago
Genocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint Inhibitors
Webcast/conference call scheduled today, July 30th at 8:00 a.m. EDTThree of five patients achieved separate RECIST responses after GEN-009 administrationGEN-009 elicited antigen-specific CD4+ and CD8+ T cell responses in 100% of treated patientsCAMBRIDGE, Mass
GlobeNewswire · 4d ago
NAK, STM among premarket losers
Seeking Alpha · 6d ago
MUX, RIOT among premarket gainers
Seeking Alpha · 07/27 12:18
Benzinga Pro's Top 5 Stocks To Watch For Mon., Jul. 27, 2020: FB, BA, ALEC, SCKT, GNCA
Today's 5 Stock Ideas:  Facebook (FB) - Will report quarterly results after market close on Wednesday. Boeing (BA) - Company to report Q2 earnings before market open on Wednesday. Alector
Benzinga · 07/27 11:56
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
SAM, SOGO, INTC and EHTH among midday movers
Seeking Alpha · 07/24 16:40
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23)
Benzinga · 07/24 11:15
Genocea Bio +16% on positive GEN-009 data
Genocea Biosciences (GNCA) Q2 results: Revenues: $0.9M. Net loss: ($11.3M) (-73.8%); loss/share: ($0.39) (+7.1%); Quick Assets: $22.1M (-44.9%). GNCA prese
seekingalpha · 07/23 17:30
Genocea Biosciences EPS beats by $0.01
Genocea Biosciences (NASDAQ:GNCA): Q2 GAAP EPS of -$0.39 beats by $0.01. Revenue of $0.91M Press Release
seekingalpha · 07/23 16:01
Genocea Biosciences shares are trading higher after the company reported Q2 earnings.
Benzinga · 07/23 14:06